IFNγ-responsiveness of endothelial cells leads to efficient angiostasis in tumours involving down-regulation of Dll4
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IFNγ-responsiveness of endothelial cells leads to efficient angiostasis in tumours involving down-regulation of Dll4
Authors
Keywords
-
Journal
JOURNAL OF PATHOLOGY
Volume 233, Issue 2, Pages 170-182
Publisher
Wiley
Online
2014-02-25
DOI
10.1002/path.4340
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential
- (2013) S. Banerjee et al. CLINICAL CANCER RESEARCH
- Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
- (2012) W.-C. Yen et al. CLINICAL CANCER RESEARCH
- Beyond Bevacizumab: Antiangiogenic Agents
- (2012) Shane Rogosin et al. Clinical Lung Cancer
- TNF signaling drives myeloid-derived suppressor cell accumulation
- (2012) Xueqiang Zhao et al. JOURNAL OF CLINICAL INVESTIGATION
- The Dll4/Notch pathway controls postangiogenic blood vessel remodeling and regression by modulating vasoconstriction and blood flow
- (2011) I. B. Lobov et al. BLOOD
- Inhibitory effects of interferon-gamma plasmid DNA on DMBA-TPA induced mouse skin carcinogenesis
- (2011) J-H Ko et al. CANCER GENE THERAPY
- TNFR2 expression on non-bone marrow-derived cells is crucial for lipopolysaccharide-induced septic shock and downregulation of soluble TNFR2 level in serum
- (2011) Shubai Liu et al. Cellular & Molecular Immunology
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- Grb-2-associated binder 1 (Gab1) regulates postnatal ischemic and VEGF-induced angiogenesis through the protein kinase A-endothelial NOS pathway
- (2011) Y. Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- VEGF and angiopoietin signaling in tumor angiogenesis and metastasis
- (2011) Pipsa Saharinen et al. TRENDS IN MOLECULAR MEDICINE
- The contribution of the Tie2+ lineage to primitive and definitive hematopoietic cells
- (2010) Yuefeng Tang et al. GENESIS
- Interferon Gamma in Successful Pregnancies1
- (2009) Shawn P. Murphy et al. BIOLOGY OF REPRODUCTION
- Responsiveness of Stromal Fibroblasts to IFN- Blocks Tumor Growth via Angiostasis
- (2009) Y. Lu et al. JOURNAL OF IMMUNOLOGY
- Reduced inducibility of SOCS3 by interferon gamma associates with higher resistance of human breast cancer lines as compared to normal mammary epithelial cells
- (2009) K. SOUCKOVA et al. NEOPLASMA
- Foxc2 Transcription Factor: A Newly Described Regulator of Angiogenesis
- (2009) Tsutomu Kume TRENDS IN CARDIOVASCULAR MEDICINE
- Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity
- (2008) K. Movahedi et al. BLOOD
- Tumor-Targeted Interferon-α Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis
- (2008) Michele De Palma et al. CANCER CELL
- Murine CD146 is widely expressed on endothelial cells and is recognized by the monoclonal antibody ME-9F1
- (2008) Arnhild Schrage et al. HISTOCHEMISTRY AND CELL BIOLOGY
- Notch signaling regulates tumor angiogenesis by diverse mechanisms
- (2008) J Dufraine et al. ONCOGENE
- Foxc Transcription Factors Directly Regulate Dll4 and Hey2 Expression by Interacting with the VEGF-Notch Signaling Pathways in Endothelial Cells
- (2008) Hisaki Hayashi et al. PLoS One
- Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells
- (2007) Laura S. Harrington et al. MICROVASCULAR RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started